Last reviewed · How we verify
Arterolane-piperaquine+mefloquine
A triple artemisinin-based combination therapy that kills malaria parasites through multiple mechanisms: artemether (artemisinin derivative) damages parasite membranes, piperaquine accumulates in parasites and disrupts hemoglobin digestion, and mefloquine interferes with parasite metabolism.
A triple artemisinin-based combination therapy that kills malaria parasites through multiple mechanisms: artemether (artemisinin derivative) damages parasite membranes, piperaquine accumulates in parasites and disrupts hemoglobin digestion, and mefloquine interferes with parasite metabolism. Used for Uncomplicated Plasmodium falciparum malaria, Malaria in endemic regions (Phase 3 development).
At a glance
| Generic name | Arterolane-piperaquine+mefloquine |
|---|---|
| Sponsor | University of Oxford |
| Drug class | Artemisinin-based combination therapy (ACT) |
| Target | Plasmodium falciparum (multiple parasite targets: heme polymerization, mitochondrial function, membrane integrity) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | Phase 3 |
Mechanism of action
Arterolane (a semi-synthetic artemisinin derivative) rapidly reduces parasite biomass by generating reactive oxygen species and damaging parasite membranes. Piperaquine, a bisquinoline, concentrates in parasites and inhibits heme polymerization, causing toxic accumulation. Mefloquine acts synergistically by disrupting parasite mitochondrial function and metabolism. The triple combination targets multiple pathways to reduce treatment duration and prevent resistance.
Approved indications
- Uncomplicated Plasmodium falciparum malaria
- Malaria in endemic regions (Phase 3 development)
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Dizziness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arterolane-piperaquine+mefloquine CI brief — competitive landscape report
- Arterolane-piperaquine+mefloquine updates RSS · CI watch RSS
- University of Oxford portfolio CI